Clinical Evaluation of Efficacy and Tolerability of HMC05 in Healthy Subjects with Normal and High-Normal Blood Pressure: A Pilot Study

Abstract

HMC05, a formulation containing eight different herbal extracts, has been used widely for several thousand years in China, Japan, and Korea as a remedy for hypertension and headache. Although its anti-inflammatory effects in mouse monocytic cell lines and anti-atherosclerotic effects in apoE-knockout mice have been reported, the pharmacodynamic effects of HMC05 in human subjects have not yet been investigated. We evaluated the efficacy and tolerability of this drug in 14 healthy male Korean subjects with normal or high-normal blood pressure (BP) in a randomized, single-blind, crossover study with a 2-week washout period. Four 500-mg tablets of HMC05 or placebo were orally administered three times daily to nine subjects with normal BP and five subjects with high-normal BP for 4 weeks. To assess the pharmacodynamic effects of HMC05, levels of high-sensitivity C-reactive protein and homocysteine, BP, and flow-mediated vasodilation were measured before and after the 4-week medication period with evaluation of tolerability. All 14 subjects completed the study, and HMC05 was well tolerated with no significant adverse events. HMC05 did not exhibit a significant BP-lowering effect in either BP group, and there were no significant differences in other pharmacodynamic values after HMC05 or placebo administration in the two groups. Further study is needed to evaluate the efficacy and tolerability of HMC05 in an adequate number of patients with hypertension.

Key words

flow‐mediated vasodilation - herbal medicine - high‐sensitivity C‐reactive protein - HMC05 - homocysteine - hypertension

References

• 1 Kim K M, Choi J Y, Yoo S-E, Park M Y, Lee B S, Ko Y H, Sung S H, Shin H-M, Park J E. HMC05, herbal extract, inhibits NF-κB expression in lipopolysaccharide treated macrophages and reduces atherosclerotic lesions in cholesterol fed mice.  J Ethnopharmacol. 2007;  114 316-324
• 2 Shin H M, Morgan K G. Vasodilation by banhabackchulchunmatang, a Chinese medicine, is associated with negative modulation of PKCα activation and NO production.  Life Sci. 2003;  74 723-732
• 3 Kearney P M, Whelton M, Reynolds K, Muntner P, Whelton P K, He J. Global burden of hypertension: analysis of worldwide data.  Lancet. 2005;  365 217-223
• 4 Shin C Y, Yun K E, Park H S. Blood pressure has a greater impact on cardiovascular mortality than other components of metabolic syndrome in Koreans.  Atherosclerosis. 2009;  205 614-619
• 5 Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate.  AAPS J. 2006;  8 E146-E152
• 6 Martin C, Cameron J, McGrath B. Mechanical and circulating biomarkers in isolated clinic hypertension.  Clin Exp Pharmacol Physiol. 2008;  35 402-408
• 7 Vasan R S. Biomarkers of cardiovascular disease: molecular basis and practical considerations.  Circulation. 2006;  113 2335-2362
• 8 Corretti M C, Anderson T J, Benjamin E J, Celermajer D, Charbonneau F, Creager M A, Deanfield J, Crexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. International Brachial Artery Reactivity Task Force: guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.  J Am Coll Cardiol. 2002;  39 257-265
• 9 Garcia R G, Celedón J, Sierra-Laguado J, Alarcón M A, Luengas C, Silva F, Arenas-Mantilla M, López-Jaramillo P. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia.  Am J Hypertens. 2007;  20 98-103
• 10 Gamboa A, Shibao C, Diedrich A, Chio L, Pohar B, Jordan J, Paranjape S, Farley G, Biaggioni I. Contribution of endothelial nitric oxide to blood pressure in humans.  Hypertension. 2007;  49 170-177
• 11 Blake G J, Ridker P M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes.  J Am Coll Cardiol. 2003;  41 (4 Suppl. S) 37S-42S
• 12 Chrysohoou C, Pitsavos C, Panagiotakos D B, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study.  Am J Hypertens. 2004;  17 568-573
• 13 Clearfield M B. C-reactive protein: a new risk assessment tool for cardiovascular disease.  J Am Osteopath Assoc. 2005;  105 409-416
• 14 Myers G L, Rifai N, Tracy R P, Roberts W L, Alexander R W, Biasucci L M, Catravas J D, Cole T G, Cooper G R, Khan B V, Kimberly M M, Stein E A, Taubert K A, Warnick G R, Waymack P P. Centers for Disease Control and Prevention and the American Heart Association workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the laboratory science discussion group.  Circulation. 2004;  110 e545-e549
• 15 Wald D S, Law M, Morris J K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.  BMJ. 2002;  325 1202-1208
• 16 Coban E, Özdoğan M, Ermis C. Plasma levels of homocysteine in patients with white-coat hypertension.  Int J Clin Pract. 2004;  58 997-999
• 17 Kim S H, Choi E J, Lee K Y, Sung S H, Shin H-M. Simultaneous determination of alkaloids and flavonoids in HMC05 preparation by HPLC-DAD.  J Liq Chromatogr Relat Technol. 2008;  31 2917-2926
• 18 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grass G, Heagerty A M, Kjeldsen S E, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder R E, Boudier H A J S, Zanchetti A. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).  J Hypertens. 2007;  25 1105-1187
• 19 Jin M, Wang F, Uthup M, Szydlowska M. Analytical performance of an enzymatic cycling method for total homocysteine measurement.  Clin Chim Acta. 2009;  399 119-120
• 20 Sartori C, Lepori M, Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans.  Pharmacol Ther. 2005;  106 209-220
• 21 Linder L, Kiowski W, Bühler F R, Lüscher T F. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.  Circulation. 1990;  81 1762-1767
• 22 Wensing G, Ochmann K, Boettcher M, Schäfer A, Kuhlmann J. Pharmacodynamic effects of an angiotensin II receptor-antagonist in phase I: comparison between healthy subjects and patients with hypertension.  Biomark Insights. 2007;  2 81-93

1 Both authors contributed equally to this work.